Oraya Therapeutics Release: Initial Three-Year Data From INTREPID Study Of Non-invasive Therapy For Wet AMD Presented At American Academy of Ophthalmology Annual Meeting
11/18/2013 10:33:25 AM
NEW ORLEANS--(BUSINESS WIRE)--Oraya® Therapeutics, Inc. announced today that initial three-year safety follow-up data from its INTREPID study of Oraya Therapy™ stereotactic radiotherapy for the treatment of wet age-related macular degeneration (AMD) were presented for the first time today during the America Academy of Ophthalmology’s (AAO) annual meeting in New Orleans. The new data from 55 patients who have reached the three-year follow-up visit offer ongoing evidence of Oraya Therapy’s favorable safety profile.
Help employers find you! Check out all the jobs and post your resume.
comments powered by